Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

3.95
+0.930030.79%
Post-market: 4.770.8200+20.76%19:59 EST
Volume:76.07M
Turnover:277.81M
Market Cap:3.89B
PE:-9.51
High:3.99
Open:3.14
Low:3.07
Close:3.02
52wk High:4.27
52wk Low:1.83
Shares:984.97M
Float Shares:194.00M
Volume Ratio:3.29
T/O Rate:39.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4153
EPS(LYR):-0.5931
ROE:78.05%
ROA:-36.89%
PB:-7.42
PE(LYR):-6.66

Loading ...

ImmunityBio Hosts Inaugural US-Saudi Biotech Alliance Summit

Reuters
·
Jan 12

BRIEF-Immunitybio Amends Sale Agreement With Jefferies LLC - SEC Filing

Reuters
·
Dec 29, 2025

Immunitybio Inc - Amends Sale Agreement With Jefferies Llc - SEC Filing

THOMSON REUTERS
·
Dec 29, 2025

Immunitybio - Amendment Authorizes Issuance of Additional $459.97 Mln of Shares Under Supplement - SEC Filing

THOMSON REUTERS
·
Dec 29, 2025

3 Growth Companies With Insider Ownership Up To 37%

Simply Wall St.
·
Dec 24, 2025

ImmunityBio Inc. Files Initial Statement of Beneficial Ownership for Director Bruce Wendel

Reuters
·
Dec 17, 2025

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 17, 2025

ImmunityBio Reports ANKTIVA Plus BCG Achieves 96% Three-Year Survival in BCG-Unresponsive Bladder Cancer

Reuters
·
Dec 16, 2025

Anktiva® With Bcg Demonstrates 96% Survival From Bladder Cancer at Three Years With Median Survival Not yet Reached in Bcg-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Dec 16, 2025

Immunitybio Inc - Anktiva Plus Bcg Shows Tolerable Safety Profile

THOMSON REUTERS
·
Dec 16, 2025

Assessing ImmunityBio (IBRX) Valuation After EMA Backs Anktiva for BCG‑Unresponsive Bladder Cancer

Simply Wall St.
·
Dec 16, 2025

ImmunityBio Sets Director Pay at $50,000 Plus $300,000 Stock Options for New Board Member

Reuters
·
Dec 16, 2025

The Bull Case For ImmunityBio (IBRX) Could Change Following EMA’s Conditional Backing Of ANKTIVA Therapy

Simply Wall St.
·
Dec 15, 2025

ImmunityBio Is Maintained at Buy by Jefferies

Dow Jones
·
Dec 13, 2025

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Dec 12, 2025

ImmunityBio Shares Gain After Bladder-Cancer Treatment Receives Recommendation From European Medicines Agency

Dow Jones
·
Dec 12, 2025

Immunitybio Receives Conditional Marketing Authorization Recommendation From the European Medicines Agency for Anktiva® With Bcg for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—a First in Europe

THOMSON REUTERS
·
Dec 12, 2025

ImmunityBio Inc. to Present at Piper Sandler 37th Annual Healthcare Conference

Reuters
·
Dec 03, 2025

Why ImmunityBio (IBRX) Is Up 13.5% After Strong Q3 Anktiva Revenue Surge Announced at Jefferies London

Simply Wall St.
·
Nov 29, 2025

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 14, 2025